article thumbnail

Otsuka’s startup bet pays off with kidney disease drug results

BioPharma Drive: Drug Pricing

A medicine the pharma acquired in a $430 million buyout of Visterra in 2018 succeeded in a Phase 3 trial in IgA nephropathy, a crowded corner of drug research.

Disease 167
article thumbnail

Allogene taps Arbor in pursuit of ‘off-the-shelf’ CAR-T therapies for autoimmune disease

BioPharma Drive: Drug Pricing

Allogene’s partnership with Arbor is designed to help the company stand out in what’s quickly become one of the industry’s hottest areas of drug research.

Therapies 184
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

5 questions facing pharma in 2025

BioPharma Drive: Drug Pricing

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

article thumbnail

The Molecular Mechanism of Resveratrol in the Treatment of Chronic Rhinosinusitis Through a Combination of Network Pharmacology and In Vitro Validation

Chemical Biology and Drug Design

This study aims to elucidate the potential mechanism of resveratrol against CRS disease through network pharmacology and further verify it through biological experiments in human nasal epithelial cells (HNEpCs). The potential targets and pathways of RES against CRS disease were predicted by network pharmacology and molecular docking.

Treatment 100
article thumbnail

In vivo preclinical models for immune-mediated inflammatory disease drug development

Crown Bioscience

In this blog we will explore immune-mediated inflammatory diseases (IMIDs) —which represent a diverse group of conditions characterized by an excessive and/or inappropriate immune response.

Disease 52
article thumbnail

An Evolving Regulatory Environment for Rare and Orphan Diseases

Advarra

A rare, or orphan, disease by definition affects a small percentage of the population — fewer than 200,000 people in the U.S. But the numbers add up, and taken together, rare diseases impact an estimated 30 million Americans. Since then, the FDA has significantly changed its approach to rare and orphan diseases.

Disease 52
article thumbnail

Unlocking Undruggable Targets: Shifting Paradigms in Modern Drug Discovery

DrugBank

Today, we're able to identify and target specific molecules involved in disease processes—a method that's much more like using a sniper rifle than throwing darts blindfolded. Among these targets are proteins, receptors, and enzymes that are fundamental to disease mechanisms.